Effects of Vigiis 101-LAB on a healthy population's gut microflora, peristalsis, immunity, and anti-oxidative capacity: A randomized, double-blind, placebo-controlled clinical study

Chien-Li Chen; Jyh-Ming Liou; Tsong-Ming Lu; Yi-Hsien Lin; Chin-Kun Wang; Tzu-Ming Pan

doi:10.1016/j.heliyon.2020.e04979

Effects of Vigiis 101-LAB on a healthy population's gut microflora, peristalsis, immunity, and anti-oxidative capacity: A randomized, double-blind, placebo-controlled clinical study

Heliyon. 2020 Sep 22;6(9):e04979. doi: 10.1016/j.heliyon.2020.e04979. eCollection 2020 Sep.

Authors

Chien-Li Chen¹, Jyh-Ming Liou², Tsong-Ming Lu³, Yi-Hsien Lin⁴, Chin-Kun Wang⁵, Tzu-Ming Pan^{1

6}

Affiliations

¹ Department of Research and Development Division, SunWay Biotech Co., Ltd., Taipei, Taiwan.
² Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.
³ Department of Neurology, Chung Shan Medical University Hospital, Taichung, Taiwan.
⁴ Division of Radiotherapy, Cheng Hsin General Hospital, Taipei, Taiwan.
⁵ School of Nutrition, Chung Shan Medical University, Taichung, Taiwan.
⁶ Department of Biochemical Science and Technology, College of Life Science, National Taiwan University, Taipei, Taiwan.

Abstract

Vigiis 101-LAB capsules are produced from the fermentation of Lactobacillus paracasei subsp. paracasei NTU 101. We tested effects of Vigiis 101-LAB capsules I or II (5 or 10 billion CFU/day, respectively) on gut microflora in clinical trial I, and on peristalsis, immunity, and anti-oxidative capacity in clinical trial II, during a 4-week randomized, double-blind, placebo-controlled, adaptive-design study. In trial I, 36 subjects were divided into capsule I and placebo groups. After 4 weeks, Bifidobacterium spp. and Lactobacillus spp. counts were significantly higher in the feces of treatment subjects, with increases of 4.01- and 4.25-fold, respectively. In trial II, 52 subjects were divided into capsule II and placebo groups. After 4 weeks, the treatment group was found to have improved motility, decreased food transit time, and significantly increased immunoglobulin G, immunoglobulin M, and antioxidant activity. Thus, daily administration of Vigiis 101 capsule II can improve peristalsis, immunity, and anti-oxidative capacity.

Keywords: Anti-oxidative capacity; Evidence-based medicine; Food microbiology; Gut microflora; Immunity; Lactobacillus paracasei subsp. paracasei NTU 101; Microbiology; Nutrition; Probiotics.